| Assay ID | Title | Year | Journal | Article |
|---|
| AID5495 | Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI). | 1999 | Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
| Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain. |
| AID21908 | Partition coefficient of octanol and water was determined | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
| Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy. |
| AID1834411 | Modulation of human 5HT2A expressed in HEK293T cells co-transfected with Galphaq-RLuc8, Ggamma1-GFP2 and Gbeta1 assessed as dissociation of Galphaq from Ggamma1 preincubated for 1 hr followed by addition of coelenterazine 400a substrate and measured after | 2021 | ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12
| Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders. |
| AID1769403 | Metabolic stability in human liver microsomes assessed as intrinsic clearance measured after 60 mins by LC-MS/MS analysis | 2021 | ACS medicinal chemistry letters, Oct-14, Volume: 12, Issue:10
| Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders. |
| AID5577 | In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI | 2003 | Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
| Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands. |
| AID5466 | Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor | 2003 | Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
| Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands. |
| AID1893756 | Agonist activity at human 5-HT2A receptor assessed as activation of calcium mobilization incubated for 2 mins by Calcium-6 dye based FLIPR assay | 2022 | ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
| Restoration of Motor Function Post-Neurological Injury Using Serotonergic Agonist. |
| AID1815952 | Agonist activity at 5-HT2A receptor (unknown origin) by calcium flux assay | 2022 | ACS medicinal chemistry letters, Apr-14, Volume: 13, Issue:4
| Improved Metabolically Stable 5-HT Receptor Modulators and the Development of New Antidepressants. |
| AID1648180 | Agonist activity at human 5-HT2A receptor expressed in Flp-In T-REx 293 cells assessed as induction of Gq-mediated calcium flux incubated for 1 hr by Flou4-AM dye based FLIPR assay relative to serotonin | 2020 | Journal of natural products, 02-28, Volume: 83, Issue:2
| Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin. |
| AID1815948 | Stability in human liver mitochondria assessed as intrinsic clearance in presence of MAO-A and MAO-B | 2022 | ACS medicinal chemistry letters, Apr-14, Volume: 13, Issue:4
| Improved Metabolically Stable 5-HT Receptor Modulators and the Development of New Antidepressants. |
| AID25806 | Ionization constant of compound was determined | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
| Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy. |
| AID185557 | Maximum 5-HT stimulation was determined in cloned rats | 2003 | Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
| Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands. |
| AID385348 | Displacement of [3H]MDL100907 from 5HT2A receptor in Sprague-Dawley rat brain by liquid scintillation spectroscopy | 2008 | Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
| The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. |
| AID1880246 | Agonist activity at human 5-HT2A receptor expressed in cells assessed as increase in calcium mobilization by Calcium-6 dye based FLIPR assay | 2022 | ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5
| 3-Pyrrolidine-indole Derivatives as 5-HT2-Selective Receptor Modulators for the Potential Treatment of Mental Disorders. |
| AID385349 | Lipophilicity of compound by immobilized artificial membrane column containing phosphatidylcholine head groups HPLC | 2008 | Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
| The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. |
| AID1834409 | Modulation of human 5HT2B expressed in HEK293T cells co-transfected with Galphaq-RLuc8, Ggamma1-GFP2 and Gbeta1 assessed as dissociation of Galphaq from Ggamma1 preincubated for 1 hr followed by addition of coelenterazine 400a substrate and measured after | 2021 | ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12
| Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders. |
| AID1769402 | Displacement of [3H]-ketanserin from human 5-HT2A receptor incubated for 90 mins by scintillation counting analysis | 2021 | ACS medicinal chemistry letters, Oct-14, Volume: 12, Issue:10
| Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders. |
| AID24170 | Partition coefficient (logP) | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
| Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy. |
| AID3864 | Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined | 2003 | Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
| Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands. |
| AID1815951 | Stability in rat brain homogenate assessed as half life | 2022 | ACS medicinal chemistry letters, Apr-14, Volume: 13, Issue:4
| Improved Metabolically Stable 5-HT Receptor Modulators and the Development of New Antidepressants. |
| AID1815949 | Stability in human liver mitochondria assessed as compound remaining in presence of MAO-A and MAO-B measured after 60 mins | 2022 | ACS medicinal chemistry letters, Apr-14, Volume: 13, Issue:4
| Improved Metabolically Stable 5-HT Receptor Modulators and the Development of New Antidepressants. |
| AID26061 | True partition coefficient corrected for ionization was determined | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
| Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy. |
| AID1782619 | Agonist activity at 5HT2A receptor (unknown origin) expressed in HEK293 cells by FLIPR calcium flux assay | 2021 | ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12
| The Psychedelic Renaissance: Addressing Potential Adverse Effects in a Therapeutic Setting. |
| AID1834413 | Modulation of human 5HT2C expressed in HEK293T cells co-transfected with Galphaq-RLuc8, Ggamma1-GFP2 and Gbeta1 assessed as dissociation of Galphaq from Ggamma1 preincubated for 1 hr followed by addition of coelenterazine 400a substrate and measured after | 2021 | ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12
| Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders. |
| AID385350 | Agonist activity at Sprague-Dawley rat 5HT2A receptor by drug discrimination assay | 2008 | Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
| The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. |
| AID1131957 | Hallucinogenic activity in human relative to mescaline | 1977 | Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
| Structure-activity studies on hallucinogenic amphetamines using molecular connectivity. |
| AID1769404 | Metabolic stability in human liver microsomes assessed as half life measured after 60 mins by LC-MS/MS analysis | 2021 | ACS medicinal chemistry letters, Oct-14, Volume: 12, Issue:10
| Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders. |
| AID1782621 | Agonist activity at 5HT2A receptor (unknown origin) expressed in HEK293 cells assessed as maximal effect by FLIPR calcium flux assay relative to control | 2021 | ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12
| The Psychedelic Renaissance: Addressing Potential Adverse Effects in a Therapeutic Setting. |
| AID1648182 | Agonist activity at mouse 5-HT2A receptor expressed in Flp-In T-REx 293 cells assessed as induction of Gq-mediated calcium flux incubated for 1 hr by Flou4-AM dye based FLIPR assay relative to serotonin | 2020 | Journal of natural products, 02-28, Volume: 83, Issue:2
| Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin. |
| AID5496 | Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate. | 1999 | Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
| Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain. |
| AID1648181 | Agonist activity at mouse 5-HT2A receptor expressed in Flp-In T-REx 293 cells assessed as induction of Gq-mediated calcium flux incubated for 1 hr by Flou4-AM dye based FLIPR assay | 2020 | Journal of natural products, 02-28, Volume: 83, Issue:2
| Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin. |
| AID1834410 | Modulation of human 5HT2C expressed in HEK293T cells co-transfected with Galphaq-RLuc8, Ggamma1-GFP2 and Gbeta1 assessed as dissociation of Galphaq from Ggamma1 preincubated for 1 hr followed by addition of coelenterazine 400a substrate and measured after | 2021 | ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12
| Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders. |
| AID1815947 | Stability in human liver mitochondria assessed as half life in presence of MAO-A and MAO-B | 2022 | ACS medicinal chemistry letters, Apr-14, Volume: 13, Issue:4
| Improved Metabolically Stable 5-HT Receptor Modulators and the Development of New Antidepressants. |
| AID1648179 | Agonist activity at human 5-HT2A receptor expressed in Flp-In T-REx 293 cells assessed as induction of Gq-mediated calcium flux incubated for 1 hr by Flou4-AM dye based FLIPR assay | 2020 | Journal of natural products, 02-28, Volume: 83, Issue:2
| Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin. |
| AID1815950 | Stability in rat brain homogenate assessed as compound remaining measured after 120 mins | 2022 | ACS medicinal chemistry letters, Apr-14, Volume: 13, Issue:4
| Improved Metabolically Stable 5-HT Receptor Modulators and the Development of New Antidepressants. |
| AID1834408 | Modulation of human 5HT2A expressed in HEK293T cells co-transfected with Galphaq-RLuc8, Ggamma1-GFP2 and Gbeta1 assessed as dissociation of Galphaq from Ggamma1 preincubated for 1 hr followed by addition of coelenterazine 400a substrate and measured after | 2021 | ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12
| Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders. |
| AID1834412 | Modulation of human 5HT2B expressed in HEK293T cells co-transfected with Galphaq-RLuc8, Ggamma1-GFP2 and Gbeta1 assessed as dissociation of Galphaq from Ggamma1 preincubated for 1 hr followed by addition of coelenterazine 400a substrate and measured after | 2021 | ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12
| Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders. |
| AID255671 | Effective concentration required for accumulation of [3H]inositol phosphate in cells stably expressing human 5-hydroxytryptamine 2C receptor determined by phosphoinositide hydrolysis assay | 2005 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
| SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. |
| AID255672 | Effective concentration required for accumulation of [3H]inositol phosphate in cells transiently expressing human 5-hydroxytryptamine 2B receptor determined by phosphoinositide hydrolysis assay | 2005 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
| SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. |
| AID255670 | Effective concentration required for accumulation of [3H]inositol phosphate in cells stably expressing human 5-hydroxytryptamine 2A receptor determined by phosphoinositide hydrolysis assay | 2005 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
| SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. |
| AID5747 | Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined | 2003 | Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
| Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |